Bristol Myers Squibb (BMY) stock jumps on UBS upgrade as investors look to January catalysts
Bristol Myers Squibb shares jumped 4.2% to $56.72 after UBS upgraded the stock to “buy” and raised its price target to $65. UBS cited upcoming catalysts but noted ongoing patent-expiry pressure through 2028. Trading volume exceeded averages as the stock outperformed peers on a down market day. Investors await the company’s Jan. 12 J.P. Morgan conference appearance and Feb. 5 quarterly results.